MAE方案治疗42例急性白血病的临床疗效分析

目的：探究MAE方案治疗急性白血病患者的临床疗效。方法：对所有患者均给予MAE方案和相应的支持治疗,观察临床疗效及不良反应。结果：42例患者经MAE方案一个或两个疗程治疗后,完全缓解25例（59.52%）,部分缓解8例（19.05%）,未缓解9例（21.43%）;有38例（占90.48%）患者于治疗6～12d内发生骨髓抑制,23例感染（54.76%）,40例（95.24%）患者有轻微消化道反应,无肝肾功能损伤、心肌酶谱改变及死亡者。结论：对急性白血病患者实施MEA治疗方案进行化疗的临床效果确切,且相对安全,值得临床应用与推广。

Clinical Analysis of MAE Program in the Treatment of 42 Cases with Acute Leukemia

Objective： To explore the clinical efficacy analysis of MAE program for the treatment of patients with acute leukemia.Method： All patients were given the MAE program and appropriate supportive care to observe the clinical efficacy and adverse reactions.Result： 42 patients were treated with the MAE program one or two courses , complete remission in 25 cases （ 59.52% ）, partial remission in 8 cases （ 19.05% ）, and no relief in 9 cases （ 21.43% ） ; 38 eases （ 90.48% ） in patients with bone marrow suppression in the treatment of 6-12 d, 23 cases of infection （ 54.76% ）, 40 eases （ 95.24% ） patients had mild gastrointestinal reactions, no liver and kidney dysfunction, myocardial enzymes change, and no one died.Conclusion： The exact implementation of the MEA treatment options for chemotherapy has clinical effect in patients with acute leukemia, and is relatively safe, worthy of clinical application and promotion.